The purpose of this chapter is to give insights into metacaspase of Leishmania protozoan parasites as arginine-specific cysteine peptidase. The physiological role of metacaspase in Leishmania is still a matter of debate, whereas its peptidase enzymatic activity has been well characterized. Among the different possible expression systems, metacaspase-deficient yeast cells (Δyca1) have been instrumental in studying the activity of Leishmania major metacaspase (LmjMCA).
Introduction

14
In 2000, Uren et al. described a group of cysteine proteases 15 orthologous to caspases but absent in mammals, which was named 16 metacaspases [1] . Metacaspases belong to the C14 family of CD 17 clan of cysteine proteases [2] and possess caspase-like domain with 18 a highly conserved catalytic dyad of histidine and cysteine. They 19 are divided into two structurally different types: type I metacas-20 pases with an additional N-terminal extension that is similar to ini-21 tiator/inflammatory caspases and type-II metacaspases with an 22 insertion of around 200 amino acids between two caspase-like sub-23 units. Interestingly, genomic analysis reveals the presence of a large 24 pool of metacaspases in unicellular and filamentous cyanobacteria 25 that are still poorly studied [3] , whereas metacaspases from plants, 26 Saccharomyces cerevisiae, and protozoan parasites have rather been 27 extensively investigated. [4] .
42
Due to the mitochondrial localization signal and the proline-43 rich sequences, LmjMCA N-and C-terminal domains could 44 preclude expression and activity measurement of metacaspase.
45
Therefore, it is necessary to limit expression and activity measure- LmjMCA). To do so, the DNA sequence encoding the catalytic 49 domain was amplified and the PCR product was inserted into the 50 pESC-His vector (Stratagene) using appropriate cloning sites [5] .
51
This vector contains a galactose inducible promoter and 52 N-terminally 6× His and C-terminal FLAG epitope encoding 53 sequences respectively allowing purification with Ni-NTA resin or 54 with murine monoclonal antibodies against the Penta-His-epitope 55 (α-His5; Qiagen) or the FLAG epitope (α-FLAG; Stratagene).
56
A single step was sufficient to enrich for enough material for spe-57 cific enzymatic activity tests (Subheading 3.6; Fig. 1 ).
58
In contrast to caspases that have strict substrate specificity 59 towards aspartic acid, metacaspases rather cleave arginines or 60 lysines at the substrate P1 position [5] [6] [7] [8] . LmjMCA has been found to be an arginine-specific cysteine 61 protease able to complement the yeast metacaspase (YCA1). In the 62 evaluation of specific recognition of the A. thaliana metacaspase 63 AtMC9 using a peptide library, amino acids valine, arginine, pro-64 line, and arginine were found to be important in positions P4, P3, 65 P2, and P1, respectively, allowing the design of the optimized tet-66 rapeptide substrate VRPR [9] . To examine the specificity of 67 LmjMCA for this peptide, the catalytic domain of LmjMCA (cd-68 LmjMCA) can be expressed in Δyca1 yeast cells and tested with the 69 fluorogenic substrate (Subheading 3.9; Fig.  2 ).
70
Enzymatic activity of cd-LmjMCA can be tested in whole yeast 71 cell lysate providing that specific substrates and inhibitors are avail-72 able. Total protein extracts of Δyca1 yeast cells expressing cd-73 LmjMCA were tested for their enzymatic activity with 74 Boc-GRR-AMC, z-GGR-AMC, and Ac-VRPR-AMC substrates in 75 the presence of different inhibitors such as a broad caspase inhibitor 76 z-VAD-fmk, the cysteine protease inhibitor E64, and the serine pro-77 tease inhibitors PMSF, leupeptin, and aprotinin (Subheading 3.5; 78 Fig. 3 ). The caspase inhibitor z-VAD-fmk produced a low but sig-79 nificant inhibition of cd-LmjMCA activity with both Boc-GRR-80 AMC (p value = 0.0008) and z-GGR-AMC (p value < 0.0001) but 81 not with the Ac-VRPR-AMC substrate. The cysteine protease inhib-82 itor E64 had no significant effect on cd-LmjMCA activity with the 83 three substrates. The serine protease inhibitors PMSF and aprotinin 84 had no effect on cd-LmjMCA activity with both Boc-GRR-AMC 85 
Materials
and z-GGR-AMC substrates, however, cd-LmjMCA activity with the Ac-VRPR-AMC substrate was increased when these two latter inhibitors were added. However, this increase was not always observed. The increase of activity of cd-LmjMCA with the Ac-VRPR-AMC substrate in the presence of PMSF and aprotinin could be due to a protective effect over cd-LmjMCA by inhibition of its degradation by other proteases. Since these experiments were done with total protein extracts, the influence of other yeast proteases cannot be excluded. Interestingly, leupeptin, a serine protease inhibitor, which can also inhibit some cysteine proteases such as calpains and cathepsins, completely abrogated cd-LmjMCA activity with all three substrates (Boc-GRR-AMC p-value < 0.0002; z-GGR-AMC pvalue < 0.001; and Ac-VRPR-AMC p-value < 0.0001). Although the structural similarity of cd-LmjMCA with caspases could explain the slight inhibition found with z-VAD-fmk for Boc-GRR-AMC and z-GGR-AMC, this inhibitor was not able to affect the activity of cd-LmjMCA towards Ac-VRPR-AMC, the most preferred substrate of this metacaspase (Fig. 3 ).
All chemicals used are of Molecular Biology grade unless specified and solutions are prepared with deionized water. When not specified, incubations are performed at room temperature. 3. 10× Dropout [4] amino acid solution (without histidine when 123 using the pESC-His vector): 200 mg/ml l-adenine hemisul-124 fate salt, 200 mg/ml l-arginine HCl, 200 mg/ml l-histidine, 125 300 mg/ml l-isoleucine, 1,000 mg/ml l-leucine, 300 mg/ml 126 l-lysine HCl, 200 mg/ml l-methionine, 500 mg/ml l-127 phenylalanine, 2,000 mg/ml l-threonine, 200 mg/ml l-128 tryptophan, 300 mg/ml l-tyrosine, 200 mg/ml l-uracil, 129 1,500 mg/ml l-valine. Pass the solution through a 0.22 μm 130 size filter and aliquot in 50-ml tubes. Store at 4 °C. 4. SD/DO/Glucose medium: for 1 L weigh 6.7 g of Yeast nitro-132 gen base without amino acids and add H2O to 850 ml. Control 133 the pH (pH 5.8). Autoclave and let cool down to 55 °C. Add 134 100 ml of the 10× DO solution (without histidine) and then 135 50 ml of 40 % glucose or galactose (filtered; final concentra-136 tion 2 %). 5. Pierce BCA protein assay kit (Thermo Scientific) with BSA as standard.
1. Lysis buffer for whole cell lysate activity test: 50 mM KH2PO4, pH 7.5, 500 mM NaCl, 1 mM EDTA, 5 mM DTT, 1 % CHAPS, 5 μg/ml Aprotinin.
2. Lysis buffer for purified cell lysate activity test: 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 % Triton X-100.
3. Washing Buffer for purified cell lysate activity test: 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 20 mM imidazole. 4. Elution Buffer for purified cell lysate activity test: 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 250 mM imidazole). 5. Amicon Ultra-4 centrifugal device (Millipore). 12. Trypsin powder (Boehringer Manheim GmbH, Germany).
13. 96-well black plates (Optiplate-96 F, PerkinElmer).
14. Spectrophotometer. 6. Ponceau S Solution: 0.5 g Ponceau S, 1 ml glacial acetic acid, 219 adjust to 100 ml with H2O. 
Methods
Yeast Transformation
13. Filter papers.
14. Plastic wrap.
15. Cassette and X-Ray film.
1. Plate Δyca1 cells (see Note 1) from frozen stock onto YPD plates using a platinum loop, which has been previously sterilized by flaming and then cooled quickly on the plate.
2. Incubate at 30 °C for 4 days and then inoculate 1 ml of YPD medium with 1 colony and vortex for 2 min.
3. Transfer to 49 ml of YPD medium (total volume 50 ml) and place on a shaker at 30 °C overnight.
4. The next day, dilute the overnight culture to OD600 0.2-0.3 in 300 ml (see Note 2) and further incubate at 30 °C with shaking for 2 h or until OD600 reaches 0.4-0.6. 5. Centrifuge at 1,000 × g for 5 min in 50 ml tubes, dilute and pool pellets in 50 ml H2O, centrifuge at 1,000 × g for 5 min at room temperature.
6. Resuspend pellet in 1.5 ml of 1× TE/1× LiAc fresh solution.
7. Add 10 μl of 10 mg/ml herring sperm carrier DNA in a 1.5-ml vial, heat at 95 °C for 5 min and quick chill on ice.
8. Leave on ice and add 1 μg of cd-LmjMCA plasmid and mix.
9. Add 100 μl of yeast cell suspension and vortex.
10. Add 600 μl of PEG1000/Tris/LiAc fresh solution and vortex for 10 s.
11. Incubate at 30 °C with shaking for 30 min.
12. Add 70 μl of DMSO from stock solution and mix by inversion at 42 °C for 15 min (heat shock).
13. Leave on ice for 2 min, then microfuge at 10,000 × g for 5 s.
14. Resuspend the pellet in 500 μl of 1× TE.
15. Dilute with 1× TE and plate 100 μl of dilutions 1:1, 1:10, 1:100, and 1:1,000 on YPD plates and incubate at 30 °C for 3 days to obtain colonies.
16. Verify that the transformation was efficient and that your cells have the desired plasmid by using standard minilysate protocol.
17. Grow overnight culture: inoculate one transformed colony into 1 ml of SD/DO/Glucose medium, vortex, transfer to 9 ml of SD/DO/Glucose medium, and incubate at 30 °C with continous shaking overnight.
18. Prepare frozen stock of transformed yeast cells: mix 700 μl of the overnight culture and 300 μl of 87 % glycerol, mix and store at -70 °C. 276 in a 100-ml Erlenmeyer flask (ten times culture volume) and 277 incubate at 30 °C with shaking for 6 h or until OD600 reaches 278 0.4-0.6.
279
4. Centrifuge 1 ml of culture at 10,000 × g for 1 min and store 280 pellet at -70 °C (non induced control).
281
5. For the galactose induction, centrifuge the culture at 1,000 × g 282 for 5 min and dilute the pellet with 10 ml of SD/DO/ 283 Galactose medium and then incubate at 30 °C with shaking 284 overnight.
285
6. Measure OD600 after at least 16 h of induction. 2. Vortex ten times, 1 min each, and collect supernatant. 6. Protein concentration in supernatant can be measured using a 311 BCA protein assay reagent with BSA as standard. 2. Resuspend the frozen pellet in 100 μl of lysis buffer, transfer to a 1.5-ml vial and add 0.08 g of glass beads.
3. Vortex ten times, 1 min each.
4. Collect and save supernatant.
5. Wash the beads with 50 μl of lysis buffer, collect and save supernatant.
6. Pool supernatants and centrifuge at 10,000 × g for 1 h at 4 °C. Collect and store supernatant at -70 °C in lysis buffer containing protease inhibitors.
7. Measure protein concentration in the supernatant using a BCA protein assay reagent with BSA as standard. 12. To test the effect of different protease inhibitors on the enzymatic activity, supplement activity reactions with the following concentrations of inhibitors: 100 μM z-VAD-fmk, 100 μM E64, 10 mM PMSF, 1 mM leupeptin, and 100 μM aprotinin.
1. Resuspend frozen pellet from a 500 ml culture after induction with galactose for 18 h in 2.5 ml of lysis buffer.
2. Add 2.5 g of glass beads (0.25-0.5 mm) and vortex ten times, 1 min each (see Note 6). 3. Collect and save supernatant.
4. Wash the glass beads with 2.5 ml of lysis buffer, collect and save supernatant.
5. Pool the supernatants, centrifuge at 10,000 × g for 1 h at 4 °C, and save supernatant (contains soluble proteins).
6. Wash 1 ml 50 % Ni-NTA resin with 2 ml of lysis buffer and add the supernatant (soluble proteins) to the washed resin. 6. Incubate on the shaker at room temperature for 2 min in water to remove excess of Ponceau S red.
7. Take a picture and mark molecular weights with a pencil.
8. Incubate on a shaker at room temperature for 10 min in water to complete destaining.
9. Incubate the membrane on the shaker for 1 h at room temperature or overnight at 4 °C in the blocking buffer.
10. Incubate the membrane on a shaker overnight at 4 °C with the first antibody.
11. Wash four times for 15 min each with TBST.
12. Incubate the membrane on a shaker for 1 h at room temperature with the secondary antibody.
13. Wash four times for 15 min each with TBST (see Note 10).
14. For membrane development, deposit the membrane on a clean glass plate.
15. Dry quickly with a filter paper.
16. Overlay 1.5 ml of a developing solution (1:1 of ECL solutions A:B for a 0.125 ml/cm 2 membrane) and wait for 2 min.
17. Dry with a filter paper and cover the membrane with a plastic wrap.
18. Insert the membrane in a cassette and expose to an X-Ray film for different times (e.g. 2 s, 10 s, 2 min, 10 min); develop the film (see Note 11). 
